Triple-negative breast cancer constitutes~ 15% of all breast cancer subtypes. Because of the
negative hormone receptor and human epidermal growth factor receptor 2 status, therapy is …

Immunotherapy has revolutionized cancer therapy and now represents a standard of care
for many tumor types, including triple-negative breast cancer. Despite the positive results …

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with
limited treatment options. Recently, there has been a growing interest in immunotherapy …

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of
breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the …

Triple negative breast cancer (TNBC) is a high-risk and aggressive malignancy
characterized by the absence of estrogen receptors (ER) and progesterone receptors (PR) …

Introduction Breast cancer cells can evade immune recognition by upregulating
programmed death-ligand 1 (PD-L1) leading to decreased T cell function. Anti-PD-1 agents …

Immunotherapy has become a mainstay of cancer treatment in many malignancies, though
its application in breast cancer remains limited. Of the breast cancer subtypes, triple …

Purpose The use of immune checkpoint inhibitors in combination with chemotherapy for the
treatment of triple-negative breast cancer is becoming more widespread as efficacy data …

Introduction Immune checkpoint inhibitors have been particularly effective in treating
cancers with robust immune microenvironments and have been successfully incorporated …

Simple Summary Triple-negative breast cancer (TNBC) is the most aggressive breast cancer
subtype accounting for approximately 10–20% of all cases. Due to a lack of actionable …